Cardiology

Semaglutide was associated with a significant reduction in risk for major adverse cardiovascular events after just 3 months of treatment in a population with established CVD.

Low-dose clorthalidone offers clinicians a new option for initiating treatment that may mitigate well-known metabolic adverse effects.

Rates of amputation in Black Americans with peripheral arterial disease are 3-times higher than that of their White counterparts. Dr Fakorede, discusses, here.

A simple RNA-based blood test can identify the risk of hypertensive disorders in pregnancy months before symptoms appear, researchers reported.

ACP 2025: Dr Fakorede outlines PAD risk amplifiers, polyvascular disease connections, and when to screen using ABI, TBI, or exercise testing in high-risk patients.

Persistent hyperglycemia between ages 17 and 24 tripled the risk of left ventricular hypertrophy and did so 5 times faster among young women, a new study found.

ACP 2025: Foluso Fakorede, MD, discusses the importance of recognizing and screening for peripheral artery disease in primary care.

An EHR advisory that combined alerts to medical assistants with escalation to clinicians increased likelihood of hypertension control by a mean 18% per month.

Your daily dose of the clinical news you may have missed.

The CART ring was superior to the Apple Watch in automated AF detection with fewer unclassified ECGs, but neither device should serve as a definitive diagnostic tool.

ACC 2025. Tirzepatide improved HF symptoms and renal function in patients with obesity-related HFpEF, regardless of CKD status, according to new findings from the SUMMIT trial.

This AF guideline topline offers an at-a-glance look at the most recent ACC/AHA guidance on diagnosis of the arrhythmia.

Semaglutide 2.4 mg significantly lowered the risk of MACE and mortality in patients with ASCVD and overweight or obesity but without diabetes, researchers reported.

Findings of the EXSTROM trial may help elucidate the mechanism by which low-dose colchicine prevents MI and stroke in adults with established CAD, experts suggest.

ACC.25. The results seen with the only oral GLP-1 mimetic reflect "a profound clinical impact" for adults at high risk for MACE who are averse to injectable therapy.

The risks to women's CV health differ, often significantly, from those faced by men, as demonstrated by 5 abstracts from the American College of Cardiology 2025 annual meeting.

Your daily dose of the clinical news you may have missed.

Five years after the COVID-19 pandemic was declared, the protean syndrome dubbed long COVID continues to affect millions; Greenspan is dedicated to helping.

ACC 2025: Black women and women in Southern states faced significantly higher rates of maternal mortality, according to a new study.

Cannabis users had a more than sixfold increased risk of MI compared to non-users, according to a new study.

Higher levels of cardiovascular health were associated with lower levels of neurofilament light chain across age, sex, race/ethnicity, and Alzheimer disease risk.

The first low-dose rivaroxaban generic tablets to be FDA approved lead a field crowded with applications for formulations of all the higher doses.

The Loss of Pulse Detection feature will begin rolling out in the US late next month.

Treatment of AD with dupilumab, compared with cyclosporine and methotrexate, was associated with significantly reduced risk of a wide range of CV outcomes at 1 year.

Your daily dose of the clinical news you may have missed.

The FDA set a PDUFA action date of December 12, 2025 for lerodalcibep, according to LIB Therapeutics.

Elevated HbA1c/HDL-C ratios significantly increased stroke risk, even after adjusting for confounding factors, reported authors of a recent study.

The Tina-quant® Lipoprotein (a) Gen.2 Molarity assay measures Lp(a) in molar units, providing a more accurate particle-based risk assessment than mass units.

Data set to be presented at ISC 2025 shows that the protective effect of propranolol was stronger for ischemic stroke compared to other stroke types.

Close monitoring for dnPPHTN during the first 2 weeks post-delivery is highly recommended for women determined to be at high risk for the hypertensive disorder of pregnancy.